Company intelligence / Profile preview

Synaptiflora

Ownership: Private
Development stage: Other

Overview

Synaptiflora is an emerging biotechnology company focused on the intersection of the human microbiome and neurological health. The company leverages its proprietary Synapti-Flow platform to identify and develop microbial-based therapies and small molecule metabolites that modulate the gut-brain axis. Their primary research aims to address high-need areas in neurodegeneration and mental health, including Alzheimer's disease and clinical depression. By targeting specific microbial pathways, Synaptiflora seeks to provide non-invasive, systemic treatments for complex central nervous system disorders.

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculeMicrobial therapy
Industry: Biotech

Beyond the preview

Go deeper on Synaptiflora.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synaptiflora.

Explore the full profile